Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Medtronic
Moodys
Baxter
McKesson

Last Updated: December 6, 2022

CLINICAL TRIALS PROFILE FOR COPAXONE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Copaxone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00039988 ↗ Treatment of Multiple Sclerosis With Copaxone and Albuterol Completed Autoimmunity Centers of Excellence N/A 2001-11-01 The purpose of this study is to determine the effects of glatiramer acetate (Copaxone) alone compared to Copaxone plus albuterol in patients with Multiple Sclerosis (MS). MS is thought to be an autoimmune disease of the central nervous system. Certain white blood cells of the immune system become abnormally active and mistakenly attack the myelin of nerve fibers. Myelin is a fatty sheath that surrounds nerve fibers and insulates the nerve like insulation around an electrical wire. Without proper myelin insulation, messages sent between the brain and other parts of the body may be confused or fail completely. Damage to myelin causes the symptoms of MS. The most common form of MS is known as relapsing-remitting (RR), where partial or total recovery occurs after attacks. Four therapies are currently approved for the treatment of MS. These therapies, however, are only moderately effective and can cause undesirable side effects. For this reason, there is a need to find new therapies that have minimal side effects and may stop the disease from getting worse.
NCT00039988 ↗ Treatment of Multiple Sclerosis With Copaxone and Albuterol Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 2001-11-01 The purpose of this study is to determine the effects of glatiramer acetate (Copaxone) alone compared to Copaxone plus albuterol in patients with Multiple Sclerosis (MS). MS is thought to be an autoimmune disease of the central nervous system. Certain white blood cells of the immune system become abnormally active and mistakenly attack the myelin of nerve fibers. Myelin is a fatty sheath that surrounds nerve fibers and insulates the nerve like insulation around an electrical wire. Without proper myelin insulation, messages sent between the brain and other parts of the body may be confused or fail completely. Damage to myelin causes the symptoms of MS. The most common form of MS is known as relapsing-remitting (RR), where partial or total recovery occurs after attacks. Four therapies are currently approved for the treatment of MS. These therapies, however, are only moderately effective and can cause undesirable side effects. For this reason, there is a need to find new therapies that have minimal side effects and may stop the disease from getting worse.
NCT00078338 ↗ Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis Completed Pfizer Phase 4 2004-02-16 The primary objective of the study is to assess the clinical efficacy of Rebif® 44 microgram (mcg) three times per week compared with Copaxone® 20 milligram (mg) daily in subjects with relapsing Multiple Sclerosis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Copaxone

Condition Name

Condition Name for Copaxone
Intervention Trials
Multiple Sclerosis 17
Relapsing Remitting Multiple Sclerosis 10
Relapsing-Remitting Multiple Sclerosis 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Copaxone
Intervention Trials
Sclerosis 42
Multiple Sclerosis 42
Multiple Sclerosis, Relapsing-Remitting 31
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Copaxone

Trials by Country

Trials by Country for Copaxone
Location Trials
United States 289
Germany 31
Canada 23
Brazil 21
Italy 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Copaxone
Location Trials
California 17
New York 15
Ohio 13
Washington 11
Texas 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Copaxone

Clinical Trial Phase

Clinical Trial Phase for Copaxone
Clinical Trial Phase Trials
Phase 4 15
Phase 3 13
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Copaxone
Clinical Trial Phase Trials
Completed 30
Terminated 7
Unknown status 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Copaxone

Sponsor Name

Sponsor Name for Copaxone
Sponsor Trials
Teva Pharmaceutical Industries 15
Teva Branded Pharmaceutical Products R&D, Inc. 12
Teva Neuroscience, Inc. 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Copaxone
Sponsor Trials
Industry 57
Other 45
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Moodys
McKinsey
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.